Co-Diagnostics, Inc. CODX
1.09
(0.06)
(5.22%)
as of 25 Sep
- Market cap
- $8.3M
- P/E
- 0.0×
Follow CODX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
25.64 | 10.83 | 5.84 | 18.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.21) | (1.09) | (0.53) | (1.87) | |
P/B ratio |
0.33 | 0.33 | 0.26 | 1.05 | |
Price to Tangible BV |
0.95 | 0.50 | 0.48 | 2.43 | |
EV/Sales |
3.11 | (8.26) | (5.62) | 13.46 | |
EV/EBITDA |
0.00 | 0.10 | 0.08 | 0.00 | |
EV/Operating CF |
(0.05) | 0.18 | 0.14 | (0.36) | |
EV/FCF |
(0.05) | 0.17 | 0.14 | (0.35) | |
Quick Ratio |
3.36 | 3.42 | 1.94 | 1.29 | |
Current Ratio |
3.81 | 3.87 | 2.28 | 1.81 | |
Net Debt/EBITDA |
1.70 | 0.45 | 0.92 | 0.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF/Net income |
1.00 | 0.24 | 0.86 | 1.14 | |
Capex/Depreciation |
(0.28) | (0.49) | (0.56) | (0.09) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,081.64% | 1,932.21% | 4,064.45% | 2,499.88% | |
Selling, General and Administrative Expense of Revenue |
1,640.23% | 915.01% | 2,035.00% | 1,184.53% | |
Intangible Assets out of Total Assets |
0.58 | 0.29 | 0.34 | 0.44 | |
Share Based Compensation of Revenue |
344.29% | 110.65% | 150.07% | 128.72% | |
Graham Net Nets |
0.70 | 1.42 | 1.03 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(288.08%) | (699.25%) | (1,736.83%) | (866.39%) | |
Free Cash Flow Yield |
(244.28%) | (442.41%) | (691.59%) | (205.60%) | |
Revenue per Share |
0.12 | 0.20 | 0.06 | 0.04 | |
Operating CF per Share |
(4.68) | (4.66) | (3.48) | (1.66) | |
Capex per Share |
(0.06) | (0.10) | (0.06) | 0.00 | |
Free Cash Flow per Share |
(4.74) | (4.76) | (3.54) | (1.66) | |
Cash per Share |
9.07 | 8.93 | 3.65 | 0.85 | |
Shareholders Equity per Share |
31.56 | 15.51 | 7.12 | 2.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
31.56 | 15.51 | 7.12 | 2.95 | |
Free Cash Flow |
(5.98) | (6.33) | (7.99) | (7.17) | |
Working Capital |
10.36 | 10.15 | 5.50 | 2.33 | |
Capital Expenditures |
(0.08) | (0.13) | (0.14) | (0.02) | |
Net Current Asset Value |
9.14 | 9.58 | 4.33 | 1.31 | |
EV/EBIT |
0.00 | 0.10 | 0.08 | 0.00 | |
Capex to Sales |
0.52 | 0.50 | 0.97 | 0.11 | |
Net Profit Margin |
(4,048.69%) | (9,755.85%) | (6,260.27%) | (3,783.14%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.58 | 0.18 | 0.11 | 0.13 | |
Average Payables |
1.82 | 2.59 | 2.37 | 1.36 | |
Average Inventory |
1.18 | 1.03 | 0.96 | 0.96 | |
Average Assets |
58.56 | 44.15 | 38.32 | 31.53 | |
Average Common Equity |
51.81 | 37.25 | 31.98 | 26.93 |
Columns are period end dates